SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RA: AN INTEGRATED ANALYSIS

被引：15
|
作者：
Smolen, J. [1 ]
Genovese, M. [2 ]
Takeuchi, T. [3 ]
Hyslop, D.
Macias, W. L. [4 ]
Rooney, T. P. [4 ]
Chen, L. [4 ]
Dickson, C. [4 ]
Riddle, J. [4 ]
Cardillo, T. [4 ]
Winthrop, K. [5 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[3] Keio Univ, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Oregon Hlth & Sci Univ, Portland, OR USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.1612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0166
引用
收藏
页码：243 / 244
页数：2
相关论文
共 50 条
  • [31] Safety profile of JAK inhibitors: a focus on baricitinib
    Cohen, Stanley B.
    LANCET RHEUMATOLOGY, 2020, 2 (06): : E313 - E314
  • [32] Safety of baricitinib in patients with alopecia areata
    Bissonnette, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (02) : 165 - 165
  • [33] The safety of baricitinib in patients with rheumatoid arthritis
    Honda, Suguru
    Harigai, Masayoshi
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 545 - 551
  • [34] Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    King, Brett
    Maari, Catherine
    Lain, Edward
    Silverberg, Jonathan I.
    Issa, Maher
    Holzwarth, Katrin
    Brinker, Dennis
    Cardillo, Tracy
    Nunes, Fabio P.
    Simpson, Eric L.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (03) : 395 - 405
  • [35] Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    Brett King
    Catherine Maari
    Edward Lain
    Jonathan I. Silverberg
    Maher Issa
    Katrin Holzwarth
    Dennis Brinker
    Tracy Cardillo
    Fabio P. Nunes
    Eric L. Simpson
    American Journal of Clinical Dermatology, 2021, 22 : 395 - 405
  • [36] LONG TERM SAFETY PROFILE OF METHOTREXATE IN PATIENTS WITH RA IN ROUTINE CARE
    Nalawade, A. B.
    Akerkar, S. M.
    Pandey, B. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 269 - 269
  • [37] Patient-Reported Outcome Response and Safety Profile in Patients With Moderately to Severely Active Rheumatoid Arthritis Treated With Baricitinib 2-mg
    Sholter, Dalton
    Wu, Jianmin
    Jia, Bochao
    Zhang, Hong
    Griffing, Kirstin
    Quebe, Amanda
    Birt, Julie
    Reis, Paulo
    Liu, Huaxiang
    Bingham, Clifton
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1109 - 1110
  • [38] Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment (vol 46, pg 7, 2019)
    Smolen, J. S.
    Genovese, M. C.
    Takeuchi, T.
    Hyslop, D. L.
    Macias, W. L.
    Rooney, T.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (12) : 1648 - 1649
  • [39] Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
    Bayat, Sara
    Tascilar, Koray
    Bohr, Daniela
    Kroenke, Gerhard
    Simon, David
    Knitza, Johannes
    Hartmann, Fabian
    Schett, Georg
    Kleyer, Arnd
    RMD OPEN, 2022, 8 (02):
  • [40] Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials
    King, Brett
    Maari, Catherine
    Lain, Edward
    Silverberg, Jonathan I.
    Issa, Maher
    Holzwarth, Katrin
    Brinker, Dennis
    Cardillo, Tracy
    Nunes, Fabio P.
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB127 - AB127
12345